Also trades as: KYNB (NASDAQ) · $vol 0M
0IL8.L LSE
Kyntra Bio, Inc.
1W: -6.9%
1M: -24.0%
3M: -17.1%
YTD: -20.6%
1Y: -32.4%
3Y: -89.7%
$6.36
-0.51 (-7.42%)
Weekly Expected Move ±5.9%
$6
$6
$6
$7
$7
Overview
News
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Cap$26.1M
52W Range0.3389-20.795
Volume3,223
Avg Volume555
Beta0.90
Dividend—
Analyst Ratings
Company Info
CEOThane Wettig
Employees34
SectorHealthcare
IndustryBiotechnology
IPO Date2018-01-29
Websitekyntrabio.com
350 Bay Street
San Francisco, CA 94133
US
San Francisco, CA 94133
US
415 978 1200
About Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biopharmaceutical enterprise focused on the entire spectrum of therapeutic innovation, from discovering new compounds to developing and commercializing them. Leveraging profound insights into hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, the company strives to engineer effective medicinal solutions for anemia, fibrotic conditions, and various forms of cancer. Founded by Thomas B. Neff on September 29, 1993, Kyntra Bio, Inc. maintains its corporate headquarters in San Francisco, California.
Latest News
No recent news
Recent Insider Trades
No insider trades found